<DOC>
	<DOCNO>NCT00162110</DOCNO>
	<brief_summary>This Phase II open-label trial evaluate efficacy , safety Erbitux patient mucinous gastrointestinal adenocarcinoma involve peritoneal surface .</brief_summary>
	<brief_title>A Trial Erbitux Recurrent Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving Peritoneal Surfaces</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Able take care self . Out bed less 50 % day Absolute neutrophil count &gt; =1,500 Platelet count &gt; =100,000 Total bilirubin count &lt; =1.5 time upper limit normal Prior epidermal growth factor receptor antibody Prior treatment Erbitux Other cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>